At today’s Annual General Meeting of Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), the Group’s Chairman, Nigel Keen, will make the following statement:
“The significantly improved underlying financial performance of the Group can clearly be seen with positive adjusted EBITDA in the first half.”
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announces an update on trading for the half-year ended 30 June 2019.
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, today announces that it has received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the United States.
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal doppler monitoring, today announces its audited results for the year ended 31 December 2018.
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, today publishes a pre-close statement in relation to the year ended 31 December 2018.
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring, today announces an update on trading for the half year ended 30 June 2018.